Researchers should prioritize larger, multicenter, randomized controlled trials to definitively establish sildenafil’s efficacy and safety across various neonatal populations with different underlying conditions. These trials should focus on well-defined endpoints, such as improved oxygen saturation, reduced mortality, and long-term neurodevelopmental outcomes.
Pharmacokinetic studies are needed to optimize sildenafil dosing regimens in neonates, accounting for individual factors like gestational age, weight, and hepatic/renal function. This will help minimize adverse effects while maximizing therapeutic benefit. We need to explore personalized medicine approaches.
Further investigation into the long-term effects of sildenafil administration on neonatal development is crucial. This includes monitoring for potential impacts on vision, hearing, and cognitive function. Studies should track children for several years post-treatment.
Exploring alternative routes of administration, such as topical application or inhaled formulations, could improve delivery and reduce potential side effects associated with oral or intravenous administration. This warrants dedicated research.
Finally, combining sildenafil with other therapeutic agents deserves investigation. Synergistic effects could improve outcomes in specific neonatal conditions. Potential combinations require careful preclinical and clinical exploration.
| Clinical Trials | Larger, multicenter RCTs with standardized endpoints. |
| Pharmacokinetics | Studies to optimize dosing based on individual factors. |
| Long-term Effects | Longitudinal studies tracking developmental outcomes. |
| Alternative Routes | Investigate topical or inhaled administration. |
| Combination Therapies | Explore synergistic effects with other medications. |
